Exagen director granted 37,500 stock options
EXAGEN INC. director Frank Stokes received a grant of stock options for 37,500 shares of common stock at an exercise price of $4.31 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
EXAGEN INC. director Frank Stokes received a grant of stock options for 37,500 shares of common stock at an exercise price of $4.31 per share. These options vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service.
Insider Trade Summary
Grant/Award: 37,500 shares
Grant/Award
1 txn
Insider
Stokes Frank
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option(right to buy) | 37,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option(right to buy) — 112,500 contracts (Direct)
Footnotes (1)
- F1. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Key Figures
New option grant: 37,500 options
Exercise price: $4.31 per share
Total options after grant: 112,500 options
+1 more
4 metrics
New option grant
37,500 options
Grant to director Frank Stokes on June 9, 2026
Exercise price
$4.31 per share
Strike price for newly granted options
Total options after grant
112,500 options
Total derivative holdings following transaction
Option expiration
June 8, 2036
Expiration date of granted options
Key Terms
Stock Option, grant/award acquisition, Common Stock, vested and exercisable
4 terms
Stock Option financial
"Stock Option(right to buy)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
grant/award acquisition financial
"transaction_action": "grant/award acquisition""
Common Stock financial
"underlying_security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vested and exercisable financial
"becomes fully vested and exercisable on the first to occur"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did EXAGEN INC. (XGN) director Frank Stokes report?
Director Frank Stokes reported receiving a grant of stock options for 37,500 shares of EXAGEN INC. common stock. The options are a compensation-related award, not an open-market purchase or sale, and therefore do not reflect a discretionary trading decision in the company’s stock.
What is the exercise price of Frank Stokes’ new EXAGEN (XGN) stock options?
The granted stock options have an exercise price of $4.31 per share of EXAGEN common stock. This is the price Stokes would pay to convert each option into one share if he chooses to exercise after the options vest and before expiration.
How many EXAGEN (XGN) options does Frank Stokes hold after this grant?
After the reported grant, Frank Stokes holds 112,500 stock options in EXAGEN INC. These options represent the total derivative position reported in this filing, combining his previous awards with the newly granted 37,500 options noted in the Form 4.
When do Frank Stokes’ new EXAGEN (XGN) stock options vest?
The 37,500 stock options vest fully on the earlier of the first anniversary of the grant date or the next annual meeting of EXAGEN stockholders. Vesting is conditioned on Stokes continuing to serve on the company’s board through the applicable vesting date.
When do Frank Stokes’ EXAGEN (XGN) stock options expire?
The newly granted EXAGEN stock options held by Frank Stokes expire on June 8, 2036. He may exercise vested options any time before this expiration date, subject to the company’s equity plan terms and any applicable trading or blackout restrictions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates